null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Ocaratuzumab ELISA Kit (GXEL00114)

SKU GXEL00114
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms AME-133v, LY2469298, 1169956-08-4
€2,252
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Ocaratuzumab ELISA Kit

Assay Genie's Ocaratuzumab ELISA Kit (SKU: GXEL00114) provides researchers with a reliable quantitative ELISA for the quantitative measurement of Ocaratuzumab in Plasma, Serum. Offering a measurement range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit is optimised for precision and ease of use in the research laboratory.

Ocaratuzumab, previously known as AME-133v, is a humanized IgG1 type monoclonal antibody targeted at CD20 antigen, which is expressed on B-lymphocytes. Ocaratuzumab is a novel Fc-engineered monoclonal antibody designed by Applied Molecular Evolution in an attempt to induce effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous dosing. Libraries of antibody Fab fragment regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks. Then, the researchers expressed and selected mutants based on increased affinity for CD20. A variable region with increased binding activity for CD20 was selected and developed as ocaratuzumab. This drug is currently being developed by Mentrik Biotech and has been investigated in the trial for the treatment of cancer and autoimmune disorders. The pre-clinical trials of ocaratuzumab in follicular lymphoma was conducted in the United States (US) and Japan in phase I/II, and a Phase I trial was conducted in US rheumatoid arthritis patients. In addition, a phase III trial in relapsed follicular lymphoma patients is underway. Compared to rituximab, ocaratuzumab was shown to ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC in pre-clinical studies. The use of ocaratuzumab in other oncology and rheumatology indications has also been developed.

Complete with standards, buffers and detection reagents, the Ocaratuzumab ELISA Kit streamlines assay set-up so you can focus on results. Choose the Ocaratuzumab ELISA Kit from Assay Genie for quality you can trust.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose